We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-13.01%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.79B
AUM Growth
-$283M
Cap. Flow
-$93.2M
Cap. Flow %
-3.34%
Top 10 Hldgs %
67.96%
Holding
104
New
24
Increased
12
Reduced
21
Closed
21

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$20M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$10.2M
3
GM icon
General Motors
GM
+$9.45M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.46M
5
CCI icon
Crown Castle
CCI
+$7.4M

Top Sells

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$21.4M
2
ACOR
Acorda Therapeutics
ACOR
+$12.8M
3
F icon
Ford
F
+$10.1M
4
TEX icon
Terex
TEX
+$9.24M
5
UAL icon
United Airlines
UAL
+$8.76M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 34.56%
2 Healthcare 22.3%
3 Financials 0.62%
4 Real Estate 0.57%
5 Materials 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FCX icon
51
CALL
Freeport-McMoran
FCX
$85.5B
$7.55M 0.27%
200,000
– –
CCI icon
52
Crown Castle
CCI
$33.2B
$7.34M 0.26%
+100,000
New +$7.4M
MDLZ icon
53
CALL
Mondelez International
MDLZ
$83.9B
$7.06M 0.25%
200,000
– –
ESRX
54
CALL
DELISTED
Express Scripts Holding Company
ESRX
$7.02M 0.25%
100,000
-100,000
-50% -$6.53M
MTOR
55
DELISTED
MERITOR, Inc.
MTOR
$6.78M 0.24%
650,000
-100,100
-13% -$782K
AVNR
56
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$6.72M 0.24%
2,000,000
-1,100,000
-35% -$4.54M
CERE
57
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$5.79M 0.21%
524,021
– –
M icon
58
CALL
Macy's
M
$6.44B
$5.34M 0.19%
100,000
-450,000
-82% -$21.8M
IMGN
59
CALL
DELISTED
Immunogen Inc
IMGN
$5.13M 0.18%
350,000
+50,000
+17% +$768K
HOUS
60
CALL
DELISTED
Anywhere Real Estate
HOUS
$4.95M 0.18%
100,000
-250,000
-71% -$11.3M
PCYC
61
CALL
DELISTED
PHARMACYCLICS INC
PCYC
$4.23M 0.15%
+40,000
New +$4.85M
GDX icon
62
CALL
VanEck Gold Miners ETF
GDX
$22.4B
$4.23M 0.15%
200,000
– –
MTG icon
63
MGIC Investment
MTG
$6.5B
$4.22M 0.15%
500,000
-250,000
-33% -$1.99M
ONIT
64
Onity Group
ONIT
$343M
$4.16M 0.15%
+5,000
New +$4.12M
SGEN
65
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$3.99M 0.14%
+100,000
New +$4.08M
SPHS
66
DELISTED
Sophiris Bio, Inc.
SPHS
$3.7M 0.13%
1,000,000
– –
AVNR
67
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$3.7M 0.13%
1,100,000
+800,000
+267% +$3.3M
CPAC
68
Cementos Pacasmayo
CPAC
$1.04B
$3.65M 0.13%
246,327
-57,360
-19% -$811K
STML
69
DELISTED
Stemline Therapeutics, Inc.
STML
$3.33M 0.12%
+170,000
New +$4.54M
BLUE
70
DELISTED
bluebird bio
BLUE
$3.15M 0.11%
11,580
– –
LEG icon
71
CALL
Leggett & Platt
LEG
$1.39B
$3.09M 0.11%
100,000
– –
NG icon
72
CALL
NovaGold Resources
NG
$2.56B
$3.05M 0.11%
1,200,000
– –
SPWR
73
DELISTED
SunPower Corporation Common Stock
SPWR
$2.98M 0.11%
+152,700
New +$3.05M
MRTX
74
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.91M 0.1%
+175,000
New +$2.99M
AGIO icon
75
Agios Pharmaceuticals
AGIO
$2.09B
$2.63M 0.09%
110,000
+40,000
+57% +$912K
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2013 Portfolio in Review

As of Q4 2013, Artal Group held 104 positions worth $2.79B, down 9.2% from $3.07B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Artal Group withdrew a net $93.2M in Q4 2013, closing 21 positions and reducing 21 holdings. Its most notable exit was Ford, an estimated $10.1M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 35% of assets, down from 36% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Artal Group opened a new position in PHARMACYCLICS INC worth $17.5M.

  • Artal Group's largest Q4 2013 buy was PHARMACYCLICS INC: 165,000 shares worth $17.5M.
  • Artal Group added most to BioMarin Pharmaceuticals in Q4 2013, an estimated $10.2M increase.
  • Artal Group's biggest Q4 2013 reduction was AUXILIUM PHARAMCEUTICALS INC, cutting an estimated $21.4M.
  • Artal Group fully exited Ford in Q4 2013, selling an estimated $10.1M.
  • Artal Group's ten largest holdings make up 68% of its $2.79B portfolio in Q4 2013.
  • Artal Group opened 24 new positions and closed 21 in Q4 2013.
  • Artal Group's portfolio value fell 9.2% quarter-over-quarter to $2.79B.

Based on Artal Group's 13F filing for Q4 2013, filed 14 Feb 2014.